Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy.

• Main Authors: Stacey D Wagner, Adam J Struck, Riti Gupta, Dylan R Farnsworth, Amy E Mahady, Katy Eichinger, Charles A Thornton, Eric T Wang, J Andrew Berglund
• Format: Article
• Language: English
• Published: Public Library of Science (PLoS) 2016-09-01
• Series: PLoS Genetics
• Online Access: http://europepmc.org/articles/PMC5082313?pdf=render
• ISSN: 1553-7390; 1553-7404

Alternative splicing is a regulated process that results in expression of specific mRNA and protein isoforms. Alternative splicing factors determine the relative abundance of each isoform. Here we focus on MBNL1, a splicing factor misregulated in the disease myotonic dystrophy. By altering the concentration of MBNL1 in cells across a broad dynamic range, we show that different splicing events require different amounts of MBNL1 for half-maximal response, and respond more or less steeply to MBNL1. Motifs around MBNL1 exon 5 were studied to assess how cis-elements mediate the MBNL1 dose-dependent splicing response. A framework was developed to estimate MBNL concentration using splicing responses alone, validated in the cell-based model, and applied to myotonic dystrophy patient muscle. Using this framework, we evaluated the ability of individual and combinations of splicing events to predict functional MBNL concentration in human biopsies, as well as their performance as biomarkers to assay mild, moderate, and severe cases of DM.